Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Stock Surges on Lung Cancer Dx Findings

NEW YORK (GenomeWeb News) – Rosetta Genomics' stock soared 72 percent in mid-afternoon trading on Nasdaq after announcing a successful clinical study on one of its lung cancer diagnostic tests.

The Rehovot, Israel-based company's share price rose $1.33 to $3.18 from yesterday's close of $1.85.

A joint study by the company and Johns Hopkins University showed that the firm's miRview squamous non-small cell lung cancer diagnostic accurately classified NSCLC samples from resection and from fine-needle aspirate cell blocks, Rosetta said.

The miRview test, offered in the US by Prometheus Laboratories under the brand name ProOnc, is a microRNA-based molecular assay that classifies NSCLCs using the expression level of a single microRNA biomarker.

Details of the research are set to be published in the January 15 issue of the American Association for Cancer Research’s journal Clinical Cancer Research.

Rosetta Genomics' CEO, Ken Berlin, said in a statement that the study validated the miRview test's "sensitivity, specificity, reproducibility, and overall reliability in helping physicians accurately make this critical lung cancer classification."

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.